title: Locoregional therapy of locally advanced breast cancer: a clinical practice guideline.
abstract: OBJECTIVE
  In female patients with locally advanced breast cancer (labc) and good response to neoadjuvant chemotherapy (nact), including endocrine therapy, what is the role of breast-conserving surgery (bcs) compared with mastectomy?In female patients with labc, is radiotherapy (rt) indicated for those who have undergone mastectomy?does locoregional rt, compared with breast or chest wall rt alone, result in a higher survival rate and lower recurrence rates?is rt indicated for those achieving a pathologic complete response (pcr) to nact?In female patients with labc who receive nact, is the most appropriate axillary staging procedure sentinel lymph node biopsy (slnb) or axillary dissection? Is slnb indicated before nact rather than at the time of surgery?How should female patients with labc that does not respond to initial nact be treated?
  
  
  METHODS
  This guideline was developed by Cancer Care Ontario's Program in Evidence-Based Care (pebc) and the Breast Cancer Disease Site Group (dsg). A systematic review was prepared based on literature searches conducted using the medline and embase databases for the period 1996 to December 11, 2013. Guidelines were located from that search and from the Web sites of major guideline organizations. The working group drafted recommendations based on the systemic review. The systematic review and recommendations were then circulated to the Breast Cancer dsg and the pebc Report Approval Panel for internal review; the revised document underwent external review. The full three-part evidence series can be found on the Cancer Care Ontario Web site.
  
  
  CONCLUSIONS
  For most patients with labc, modified radical mastectomy should be considered the standard of care. For some patients with noninflammatory labc, bcs can be considered on a case-by-case basis when the surgeon deems that the disease can be fully resected and the patient expresses a strong preference for breast preservation.For patients with labc, rt after mastectomy is recommended.It is recommended that, after bcs or mastectomy, patients with labc receive locoregional rt encompassing the breast or chest wall and local node-bearing areas.It is recommended that postoperative rt remain the standard of care for patients with labc who achieve pcr to nact.It is recommended that axillary dissection remain the standard of care for axillary staging in labc, with the judicious use of slnb in patients who are advised of the limitations of the current data.Although slnb either before or after nact is technically feasible, the data are insufficient to make any recommendation about the optimal timing of slnb with respect to nact. Limited data suggest higher sentinel lymph node identification rates and lower false negative identification rates when slnb is conducted before nact; however, those data must be balanced against the requirement for two operations if slnb is not performed at the time of resection of the main tumour.It is recommended that patients receiving neoadjuvant anthracycline-taxane-based therapy (or other sequential regimens) whose tumours do not respond to the initial agent or agents, or who experience disease progression, be expedited to the next agent or agents of the regimen.For patients who, in the opinion of the treating physician, fail to respond or progress on first-line nact, several therapeutic options can be considered, including second-line chemotherapy, hormonal therapy (if appropriate), rt, or immediate surgery (if technically feasible). Treatment should be individualized through discussion at a multidisciplinary case conference, considering tumour characteristics, patient factors and preferences, and risk of adverse effects.It is recommended that prospective randomized clinical trials be designed for patients with labc who fail to respond to nact so that more definitive treatment recommendations can be developed.
authors.affiliation: Surgical Oncology, London Regional Cancer Program, London Health Sciences Centre; and Departments of Surgery and Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON.
authors.forename: M
authors.initials: M
authors.lastname: Brackstone
authors.affiliation: Program in Evidence-Based Care, Cancer Care Ontario; and Department of Oncology, McMaster University, Hamilton, ON.
authors.forename: G G
authors.initials: GG
authors.lastname: Fletcher
authors.affiliation: Juravinski Cancer Centre, Hamilton Health Sciences; and Department of Oncology, Division of Radiation Oncology, McMaster University, Hamilton, ON.
authors.forename: I S
authors.initials: IS
authors.lastname: Dayes
authors.affiliation: Department of Oncology, Queen's University, Kingston, ON.
authors.forename: Y
authors.initials: Y
authors.lastname: Madarnas
authors.affiliation: Cancer Centre of Southeastern Ontario, Kingston General Hospital; and Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON.
authors.forename: S K
authors.initials: SK
authors.lastname: SenGupta
authors.affiliation: The Ottawa Hospital Cancer Centre; and Department of Medicine, Division of Medical Oncology, University of Ottawa, Ottawa, ON.
authors.forename: S
authors.initials: S
authors.lastname: Verma
keywords: Locally advanced breast cancer; labc; locoregional disease; mastectomy; neoadjuvant chemotherapy; pathologic complete response; radiotherapy; slnb
references.citation: Lancet. 2011 Nov 12;378(9804):1707-16
references.pmid: 22019144
references.citation: J Clin Oncol. 2015 Jan 20;33(3):258-64
references.pmid: 25452445
references.citation: Acta Oncol. 2006;45(5):517-27
references.pmid: 16864164
references.citation: Lancet. 2000 May 20;355(9217):1757-70
references.pmid: 10832826
references.citation: J Clin Oncol. 2001 Nov 15;19(22):4224-37
references.pmid: 11709566
references.citation: J Surg Oncol. 2008 Nov 1;98(6):403-6
references.pmid: 18683193
references.citation: J Surg Oncol. 2003 Dec;84(4):192-7
references.pmid: 14756429
references.citation: Clin Breast Cancer. 2003 Dec;4(5):361-3
references.pmid: 14715112
references.citation: J Clin Oncol. 1995 Feb;13(2):502-12
references.pmid: 7844612
references.citation: Ann Surg. 2015 Mar;261(3):547-52
references.pmid: 25664534
references.citation: Lancet. 2005 Dec 17;366(9503):2087-106
references.pmid: 16360786
references.citation: J Clin Oncol. 2012 Nov 10;30(32):3960-6
references.pmid: 23032615
references.citation: N Engl J Med. 1998 Oct 1;339(14):941-6
references.pmid: 9753708
references.citation: J Clin Oncol. 2007 Aug 20;25(24):3657-63
references.pmid: 17485711
references.citation: Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):860-6
references.pmid: 23664327
references.citation: Eur J Cancer. 2007 Mar;43(4):718-24
references.pmid: 17240136
references.citation: Acta Oncol. 2010;49(1):24-34
references.pmid: 20100142
references.citation: Curr Oncol. 2015 Mar;22(Suppl 1):S54-66
references.pmid: 25848339
references.citation: Breast Cancer Res Treat. 2010 Aug;123(1):197-202
references.pmid: 20582466
references.citation: Radiat Oncol. 2013 Nov 14;8:267
references.pmid: 24225206
references.citation: Breast Cancer Res Treat. 2009 May;115(1):101-13
references.pmid: 18484198
references.citation: J Clin Oncol. 1998 Mar;16(3):1226-31
references.pmid: 9508211
references.citation: Ann Oncol. 2011 Mar;22(3):515-523
references.pmid: 20603440
references.citation: Lancet Oncol. 2013 Jun;14(7):609-18
references.pmid: 23683750
references.citation: J Clin Oncol. 2006 May 1;24(13):2019-27
references.pmid: 16606972
references.citation: J Natl Cancer Inst. 2008 Apr 16;100(8):542-51
references.pmid: 18398097
references.citation: Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):e35-41
references.pmid: 22342092
references.citation: Ann Surg. 2010 Sep;252(3):426-32; discussion 432-3
references.pmid: 20739842
references.citation: J Clin Oncol. 2000 Mar;18(6):1220-9
references.pmid: 10715291
references.citation: CMAJ. 2004 Mar 16;170(6):983-94
references.pmid: 15023926
references.citation: N Engl J Med. 1995 Nov 30;333(22):1444-55
references.pmid: 7477144
references.citation: Int J Cancer. 2000 May 1;86(3):408-15
references.pmid: 10760830
references.citation: J Natl Cancer Inst Monogr. 2001;(30):96-102
references.pmid: 11773300
references.citation: J Clin Oncol. 2003 Jul 15;21(14):2713-8
references.pmid: 12860949
references.citation: Lancet. 2014 Jun 21;383(9935):2127-35
references.pmid: 24656685
references.citation: Ann Oncol. 1999 Jan;10(1):47-52
references.pmid: 10076721
references.citation: JAMA. 2013 Oct 9;310(14):1455-61
references.pmid: 24101169
references.citation: Cancer. 2004 Jun 15;100(12):2512-32
references.pmid: 15197792
references.citation: Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):494-503
references.pmid: 22579377
references.citation: J Clin Oncol. 2008 Feb 10;26(5):778-85
references.pmid: 18258986
references.citation: Zhonghua Yi Xue Za Zhi. 2012 Sep 25;92(36):2538-41
references.pmid: 23158793